Procedures Manual - Medicines registration in Madagascar - 2016 version
This policy guideIine is intended for use by healthcare professionals invoIved in the management of Covid-19 in South Africa. The document provides guidance on diagnostic tests available, on antigen test performance and accessibility. 1t focuses on key issues such as when to
Perform antigen tests... how to use and interpret results. Capturing and reporting testing information is also covered.
more
• Leptospirosis is a disease that is caused by
spirochete bacteria in the genus Leptospira.
There are 10 pathogenic species, and more
than 250 pathogenic serovars.
• While leptospirosis occurs worldwide, it is
more common in tropical or sub-tropical
climates.
The 2014–2015 Ebola epidemic in western Africa was the longest and most deadly Ebola epidemic in history, resulting in 28,616 cases and 11,310 deaths in Guinea, Liberia, and Sierra Leone. The Ebola virus has been known since 1976, when two separate outbreaks were identified in the Democratic Repub...lic of Congo (then Zaire) and South Sudan (then Sudan). However, because all Ebola outbreaks prior to that in West Africa in 2014–2015 were relatively isolated and of short duration, little was known about how to best manage patients to improve survival, and there were no approved therapeutics or vaccines. When the World Heath Organization declared the 2014-2015 epidemic a public health emergency of international concern in August 2014, several teams began conducting formal clinical trials in the Ebola affected countries during the outbreak.
more
ຢາຕ້ານເຊື້ອຈຸລະຊີບ (Antimicrobial medicines) ມີຄວາມສໍາຄັນຫຼາຍຕໍ່ວຽກງານການແພດ, ສາທາລະນະສຸກ, ສຸຂະພາບສັດ ແລະ ການຜະລິດອາຫານ. ເນ...່ອງຈາກວ່າ ຢາດັ່ງກ່າວນີ້ ແມ່ນໃຊ້ເພື່ອປ້ອງກັນ ແລະ ປິ່ນປົວພະຍາດຊືມເຊື້ອ ທີ່ມີ ຈໍາພວກເຊື້ອຈຸລິນຊີ (Bacteria) ເປັນຫນື່ງໃນສາເຫດທີ່ເຮັດໃຫ້ຄົນ ແລະ ສັດເສຍຊີວິດ ໃຫ້ຫຼຸດລົງໄດ້ ແລະ ມີບົດບາດຫຼາຍໃນວົງ ການແພດແຜນປະຈຸບັນ ເປັນຕົ້ນແມ່ນ ການຜ່າຕັດ ຊຶ່ງມີຄວາມສ່ຽງຕໍ່ການຕິດເຊື້ອໄດ້ງ່າຍຈຶ່ງຈໍາເປັນຕ້ອງໄດ້ເພິ່ງພາຢາຕ້ານເຊື້ອຈຸລະ ຊີບ ທີ່ມີປະສິດທິພາບເພື່ອປ້ອງກັນ ແລະ ປິ່ນປົວການຕິດເຊື້ອທີ່ອາດເກີດຂຶ້ນ. ນອກຈາກນີ້ແລ້ວ ມັນຍັງມີຄວາມຈໍາເປັນສໍາລັບ ປ້ອງກັນ ແລະ ປິ່ນປົວ ໃນວຽກງານສັດຕະວະແພດ ແລະ ການກະສິກໍາ ເປັນຕົ້ນ: ການລ້ຽງສັດ, ການປະມົງ, ການປູກຝັງ ແລະ ມີຄວາມສໍາຄັນຕໍ່ ສຸຂະພາບສັດ ພືດ ຕ່ອງໂສ້ການຜະລິດອາຫານ ແລະ ເສດຖະກິດຂອງຊາດອີກດ້ວຍ.
more
Downloaded from https://aidsinfo.nih.gov/guidelines on 10/19/2019
Developed by the HHS Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV—A Working Group of the Office
of AIDS Research Advisory Council (OARAC)
Glob Heart . 2020 Oct 13;15(1):69. doi: 10.5334/gh.891.
The new treatment recommendations that extend the 2018 treat all recommendation for adults with chronic HCV infection to include adolescents and children down to 3 years, and to align the existing recommended pangenotypic direct-acting antiviral (DAA) regimens (SOF/DCV, SOF/VEL and G/P) for adults, ...to those for adolescents and children. This alignment is expected to simplify procurement, promote access to treatment among children in low- and middle-income countries and contribute to global efforts to eliminate the disease
more
16-17 march 2015, Geneva, Switzerland
Meeting report
Technical Update
HIV Treatment
July 2017
The objectives of these WHO guidelines are to provide updated evidence- based recommendations for the treatment of persons with hepatitis C infection using, where possible, all DAA-only combinations. The guidelines also provide recommendations on the preferred regimens based on a patient’s HCV gen...otype and clinical history, and assess the appropriateness of continued use of certain medicines. This document also includes existing recommendations on screening for HCV infection and care of persons infected with HCV that were first issued in 2014
more
Rreport of a WHO Consultative Meeting Kolkata India 2012
The core of the strategy is the goal for all patients to have better overall care, so that the numbers of deaths and cases of disability are reduced by 50% before 2030. For this to be achieved, four strategic aims will be pursued.
Empower and engage communities,
Ensure safe, effective trea...tment,
Strengthen health systems, and
Increase partnerships, coordination and resources Strong collaboration
more
These guidelines provide updated evidence-based recommendations on the priority HCV-related topics from the 2018 WHO Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C infection and the 2017 WHO Guidelines on hepatitis B and C testing. These priority areas are:
... direct-acting antiviral (DAA) treatment of adolescents and children ages ≥3 years of age
simplified HCV service delivery (decentralization, integration and task sharing)
HCV diagnostics – use of point-of-care (POC) HCV ribonucleic acid (RNA) assays and reflex HCV RNA testing.
These guidelines also update existing chapters without new recommendations, such as the inclusion of new manufacturers’ protocols on the use of dried blood spot (DBS) for HCV RNA testing and new data to inform the limit of detection for HCV RNA assays as a test of cure, in addition to their use for diagnosis.
more
- Conference summary report
Examination of the business behavior of Boehringer Ingelheim, Bayer and Baxter in India
This document lays out economic arguments for investing in the Access to COVID-19 Tools Accelerator (ACT-Accelerator). Framed within an overall context that recognizes the broader human health and societal impacts of the COVID-19 crisis, ACT-Accelerator's Economic Investment Case argues that investm...ent in ACT-Accelerator is the world’s best bet and most viable solution for restarting the global economy. It is intended for governments, multilaterals, civil society, businesses and foundations and all those interested in the work required to change the course of the pandemic. The global deployment of ACT-Accelerator’s comprehensive package of tools will reduce the severity of COVID-19 disease, enabling countries to transition out of the crisis thereby restarting domestic and international economic engines driving our global economy.
more
Towards a world free of tuberculosis
WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines.
Updated risk rates for hospital admission in patients with non-severe COVID-19
The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19.
The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients.
This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines:
**High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%.
**Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%.
Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk.
Review of COVID-19 treatments for people with non-severe COVID-19
WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022.
If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead.
WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission.
For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol.
WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials.
The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials.
more